Fujian Provincial Hospital
Fuzhou, Fujian, 350001, China
NCT Number: NCT01895023
Sevoflurane is frequently used for pediatric anesthesia because it has low pungency and rapid onset and offset of action.The reported incidence of emergence agitation (EA) following sevoflurane anesthesia varies from 10-80%. Despite its spontaneous resolution, EA is still considered as a potentially serious complication because of the risks of self-injury, and because of the stress caused to both caregivers and families.
Dexmedetomidine, an Alpha2-adrenoceptor agonist with sedative, analgesic, and anxiolytic actions, has been used in pediatric populations.Several prospective clinical trials in children have shown that dexmedetomidine significantly reduces the incidence of EA prior to recovery from sevoflurane anesthesia. However, the effect of dexmedetomidine premedication on emergence agitation has not been fully evaluated. The purpose of the present study was to verify the hypothesis that intranasal premedication with dexmedetomidine is effective in reducing emergence agitation after sevoflurane anaesthesia.
Looking for future studies?
Notify Me2 year–6 year
All sexes
Interventional
Phase 4
Fuzhou, Fujian, 350001, China
Emergence agitation was assessed using the Pediatric Anesthesia Emergence Delirium (PAED) scale.The PAED scale contains five items (eye contact, purposefulness of actions,awareness of surroundings, restlessness and consolability), each scored on a 0 to 4 scale, for a maximum of 20 points.
A perfectly calm child scores 0 and extreme agitation corresponds to 20 points. The peak EA score was recorded. Agitation scores < 10 were interpreted as an absence of agitation, scores>= 10 were regarded as presence of agitation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
Other names: alpha2-adrenoceptor agonist
The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
Other names: GABA modulators
The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
Other names: sodium chloride injection (0.9%Nacl)
Time frame: participants will be followed for the duration of PACU stay, an expected average of 1 hour
Emergence agitation was assessed using the Pediatric Anesthesia Emergence Delirium (PAED) scale.The PEAD scale contains five items (eye contact, purposefulness of actions,awareness of surroundings, restlessness and consolability), each scored on a 0 to 4 scale, for a maximum of 20 points.
A perfectly calm child scores 0 and extreme agitation corresponds to 20 points. The peak EA score was recorded. scores>= 10 were regarded as presence of agitation.
Time frame: up to 24 hours
Postoperative vomiting was assessed using a numeric rank score, where 0 = no vomiting,1 = vomited once, and 2 = vomited twice or more
Time frame: participants will be followed for the duration of PACU stay, an expected average of 1 hour
A Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) was used to measure five categories of pain related behaviour, each scored from 0, 1 or 2, for a maximum score of 10.
Time frame: up to 1 hour
the time to the first response to a simple verbal command
Time frame: participants will be followed for the duration of PACU stay, an expected average of 1 hour
The subject was discharged from the PACU when they met the institutional guidelines of level of consciousness and comfort.
Yao Yusheng
Other
Dexmedetomidine Versus Midazolam Premedication on Emergence Agitation After Strabismus Surgery in Children
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06176625
Behavior, Behavioral Symptoms
Baltimore, Maryland, United States
View Trial DetailsNCT06970249
Behavior, Confusion
Iksan, Jeollabukdo, South Korea
View Trial DetailsNCT02509221
Confusion, Delirium
Syracuse, New York, United States
View Trial DetailsNCT04816162
Confusion, Delirium
Zagazig, Alsharqia, Egypt
View Trial Details